Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1995-8-23
|
pubmed:abstractText |
Efficacy of orally available, selective vasopressin V1 and V2 receptor antagonists on the developing and established stage of DOCA-salt hypertension was investigated. Twenty-nine Wistar rats were heminephrectomized, and administered DOCA (50 mg/kg; intraperitoneally twice a week) and salt (5% NaCl diet) from week 0 to the end of study. Group 1 rats were served as control. Group 2 and 5 rats were given a V1 antagonist, and groups 3 and 6 rats were given a V2 antagonist, while groups 4 and 7 rats received both V1 and V2 antagonists. Each drug was started to groups 2, 3 and 4 at week 0, and to groups 5, 6 and 7 at week 4. Significant amelioration of the increase in blood pressure was observed in groups 3 and 4 at week 10, and a reduction in blood pressure occurred in groups 6 and 7 at week 10. Otherwise, a V1 antagonist alone slightly attenuated blood pressure rise in the group 2 without significance, and failed to lower blood pressure of the group 5 during the study. These results suggest that both V1 and V2 agonisms are involved in an increase in blood pressure at the developing stage of DOCA-salt hypertension, and that V2 agonism, but not V1 plays a major role in the maintenance of high blood pressure at the established stage.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Benzazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Desoxycorticosterone,
http://linkedlifedata.com/resource/pubmed/chemical/OPC 21268,
http://linkedlifedata.com/resource/pubmed/chemical/OPC 31260,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Vasopressin,
http://linkedlifedata.com/resource/pubmed/chemical/Sodium Chloride
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1064-1963
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
469-83
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:7613523-Administration, Oral,
pubmed-meshheading:7613523-Animals,
pubmed-meshheading:7613523-Benzazepines,
pubmed-meshheading:7613523-Blood Pressure,
pubmed-meshheading:7613523-Body Weight,
pubmed-meshheading:7613523-Desoxycorticosterone,
pubmed-meshheading:7613523-Hypertension,
pubmed-meshheading:7613523-Male,
pubmed-meshheading:7613523-Piperidines,
pubmed-meshheading:7613523-Quinolones,
pubmed-meshheading:7613523-Random Allocation,
pubmed-meshheading:7613523-Rats,
pubmed-meshheading:7613523-Rats, Wistar,
pubmed-meshheading:7613523-Receptors, Vasopressin,
pubmed-meshheading:7613523-Sodium Chloride
|
pubmed:year |
1995
|
pubmed:articleTitle |
Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats.
|
pubmed:affiliation |
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article
|